{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60000958",
    "licUnit": "1",
    "validDate": "2029-08-18 00:00:00.000",
    "issueDate": "2014-08-18 00:00:00.000",
    "oriIssueDate": "2014-08-18",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000095807",
    "prodNameC": "益伏注射劑 5毫克\/毫升",
    "prodNameE": "YERVOY (ipilimumab) Injection 5mg\/mL",
    "indicationsName": [
        "1.無法切除或轉移性黑色素瘤：併用 nivolumab 適用於治療無法切除或轉移性黑色素瘤之12歲以上病人。  2.晚期腎細胞癌：併用 nivolumab 適用於中度\/重度風險 (intermediate \/poor risk) 晚期腎細胞癌 (RCC)成人病人的第一線治療。  3.高度微衛星不穩定性(MSI-H)或錯配修復缺陷(dMMR)的轉移性大腸直腸癌：併用nivolumab適用於接受fluoropyrimidine、oxaliplatin和irinotecan治療後疾病惡化之具有高度微衛星不穩定性(MSI-H)或錯配修復缺陷(dMMR)的轉移性大腸直腸癌(CRC)成人病人。  4.肝細胞癌：併用 nivolumab 適用於治療先前曾接受sorafenib治療的肝細胞癌 (HCC) 成人病人。  5.轉移性或復發性非小細胞肺癌：  (1)併用 nivolumab 適用於帶有PD-L1(≧1%)且不具EGFR或ALK腫瘤基因異常的成年轉移性或復發性非小細胞肺癌(NSCLC)病人的第一線治療。  (2)併用 nivolumab 及2個週期含鉑化學治療適用於不具EGFR或ALK腫瘤基因異常的成年轉移性或復發性非小細胞肺癌(NSCLC)病人的第一線治療。  6.惡性肋膜間皮瘤：併用 nivolumab 適用於無法切除之惡性肋膜間皮瘤成人病人的第一線治療。  7.食道癌：併用 nivolumab 適用於晚期或轉移性食道鱗狀細胞癌 (ESCC) 成人病人的第一線治療。  "
    ],
    "does": "227D",
    "packageUnit": [
        {
            "packageSpec": "10毫升",
            "packageUnit": "1A"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": null,
    "mainCategory": null,
    "drBaseId": "DD8D1307-EFBE-4224-B926-D18E697F5666",
    "subCategory": [],
    "ingredientsDesc": [
        "Ipilimumab"
    ],
    "restraintItemsCode": [
        "02",
        "07"
    ],
    "applicantName": "台灣必治妥施貴寶股份有限公司",
    "applicantAddr": "台北市松山區健康路156號4樓、5樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": null,
    "mdKind": [],
    "monitorDate": "2019-08-18",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "BD7EA9A8-F26A-4549-B73C-1DEEE3C61508",
            "factoryCode": "1",
            "factoryName": "BRISTOL-MYERS SQUIBB HOLDINGS PHARMA LTD.",
            "factoryAddr": "BO TIERRAS NUEVAS,ROUTE 686,KM 2.3,MANATI,PUERTO RICO 00674,U.S.A.",
            "factoryCompanyAddr": "ROUTE 206 AND PROVINCE LINE ROAD,PRINCETON,NEW JERSEY 08543,U.S.A.",
            "countryCode": "PR",
            "processCode": [
                {
                    "value": "3R",
                    "name": "成品及包裝廠"
                }
            ],
            "processCodeStr": "3R;成品及包裝廠",
            "factoryKind": "M",
            "factoryNo": "FPR0021000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "C4FB2A59-2245-4B70-8E99-B80C65C352C7",
            "factoryCode": "1",
            "factoryName": "BAXTER PHARMACEUTICAL SOLUTIONS LLC",
            "factoryAddr": "927 SOUTH CURRY PIKE, BLOOMINGTON, INDIANA 47403, USA",
            "factoryCompanyAddr": null,
            "countryCode": "US",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FUS0485000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "3F670DB5-E5F8-41CF-B0FF-B04995320B02",
            "factoryCode": "2",
            "factoryName": "CATALENT ANAGNI S.R.L. ",
            "factoryAddr": "Localita’Fontana del Ceraso snc, Strada Provinciale 12 Casilina, 41, Anagni (FR), 03012 Italy",
            "factoryCompanyAddr": "",
            "countryCode": "IT",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FIT0404000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "25AB4513-319F-43AB-B9B6-AFF022C6B817",
            "factoryCode": "2",
            "factoryName": "Samsung Biologics Co. Ltd.",
            "factoryAddr": "300 Songdo bio-daero, Yeonsu-gu, Incheon City, Korea 21987, Korea Republic",
            "factoryCompanyAddr": "",
            "countryCode": "KR",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FKR0186000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "AD680541-078B-458C-B4FF-D6C8C165DCEF",
            "factoryCode": "2",
            "factoryName": "Lotte Biologics USA, LLC",
            "factoryAddr": "6000 Thompson Road East Syracuse, New York 13057, USA",
            "factoryCompanyAddr": "",
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0037200",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013004100",
            "ingredientsName": "Ipilimumab",
            "ingredientsDesc": "Ipilimumab",
            "concentDesc": "",
            "concent": "5.0000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FX04"
        }
    ],
    "licBaseId": "69CB2371-8414-4AF5-8F47-BB6D7CA0EC11"
}